Microgenics Corporation

Microgenics Corporation, operating through its Clinical Diagnostics Division and doing business as Microgenics Corp, manufactures and supplies immunoassay reagent test kits for clinical toxicology screening and substance detection to the Department of Defense and Veterans Affairs as a prime contractor on firm fixed-price delivery orders and single-award indefinite delivery contracts, with no set-aside designations across its federal portfolio. A subsidiary of Thermo Electron Corporation headquartered in Fremont, California, Microgenics competes on a full-and-open basis without small business set-aside participation, reflecting its established competitive position in the federal diagnostic reagent marketplace.

Microgenics' capability footprint centers on high-precision immunoassay reagent test kits designed to detect controlled substances in human urine samples. The company manufactures specialized products including benzodiazepine reagent kits (compatible with Beckman Coulter AU5800 series systems), DRI opiate 500ML reagent test kits, MDMA/MDA reagent kits, amphetamine and methamphetamine reagent kits, hydrocodone reagent kits, oxycodone and oxymorphone reagents, and benzoylecgonine (BZE) immunoassay reagents. Representative recent work includes a $175,705.20 delivery order from the Air Education and Training Command (December 2025) for benzodiazepine reagent kits; a $121,041.36 delivery order from the Defense Health Agency (April 2021) for benzodiazepine reagent kits supporting Tripler Army Medical Center in Hawaii; and a $235,125.00 sole-source purchase order from the Defense Health Agency (January 2024) for Negative Urine Calibrator supplies to Tripler Army Medical Center. Work is performed at Microgenics' facilities in Fremont, California, with subordinate performance locations at San Antonio, Texas; Pomona, California; and other military medical treatment facilities nationwide.

Customer concentration is extreme and highly concentrated in Navy medical logistics. The top five funding agencies account for approximately 70 percent of awards. The Department of the Navy Bureau of Medicine and Surgery dominates with 673 awards and $57 million combined potential value, followed distantly by the Department of the Army Medical Command (173 awards, $8.5 million), Air Education and Training Command (105 awards, $5.5 million), Veterans Integrated Service Network 23 (32 awards, $3 million), and Defense Health Agency (44 awards, $1.7 million). This concentration reflects Microgenics' role as a specialized supplier to the Department of Defense Drug Demand Reduction Program—the primary customer driver across all awards.

Microgenics holds multiple single-award indefinite delivery contracts serving as parent vehicles for task orders. The Navy Bureau of Medicine and Surgery awarded a $1,154,822.40 single-award IDC for MDMA/MDA reagent kits (March 15, 2024, completion March 14, 2029); a $775,453.50 single-award IDC for AMP and METH reagent kits (January 30, 2025, completion January 29, 2030); a $775,453.50 single-award IDC for benzoylecgonine (BZE) immunoassay reagent kits (March 18, 2026, completion March 17, 2031); and a $750,435.30 single-award IDC for DRI Opiate 500ML Reagent Test Kits (June 1, 2023, completion May 31, 2028). Veterans Integrated Service Network 23 awarded a $852,120.80 single-award IDC for toxicology reagents (December 8, 2024, completion September 30, 2029). The Navy Bureau of Medicine and Surgery also maintains a $491,914.60 single-award IDC for DRI Hydrocodone Reagent Kits (April 26, 2024, completion October 31, 2029). Microgenics also holds a Federal Supply Schedule position (V797P5752X) supporting 189 task orders worth $1.1 million combined potential value. Delivery orders against these vehicles are consistently firm fixed-price with individual ceiling values ranging from approximately $1,000 to $235,000, with most orders valued between $6,000 and $70,000.

Activity has remained flat to slightly declining year over year—74 awards in 2022, 76 in 2023, 55 in 2024, 68 in 2025, and 17 recorded by July 2026. The source data captures awards through September 1, 2026. Twelve awards with ultimate completion dates in the next twenty-four months carry combined potential value of $710 thousand, presenting modest recompete exposure relative to the overall $83.3 million portfolio.

Microgenics operates entirely as a prime contractor with no subcontract footprint recorded in the source data. The company's award history reflects direct delivery to Navy, Army, Air Force, and VA medical facilities without intermediate teaming relationships.

The vendor's product portfolio is categorized almost entirely under NAICS 325413 (In-Vitro Diagnostic Substance Manufacturing), accounting for 1,159 of 1,475 awards. PSC code 6550 (In Vitro Diagnostic Substances, Reagents, Test Kits and Sets) dominates with 952 awards, supplemented by PSC 6505 (Drugs and Biologicals) with 185 awards. The concentration reflects deep specialization in clinical diagnostics reagents rather than diversification across laboratory equipment, maintenance, or broader medical supply categories, though 17 awards for electronic equipment repair and maintenance and 12 for hospital equipment wholesaling represent minor diversification.

Microgenics' parent company, Thermo Electron Corporation, is a for-profit manufacturer and holder of federal contract vehicles in its own right, providing financial and operational support to the Clinical Diagnostics Division. The parent company's presence does not appear in Microgenics' federal award footprint; awards are issued to and obligated against Microgenics Corporation exclusively, with performance by Microgenics' facilities and workforce.